



Insights On Reye's Syndrome - An Uncommon But Serious Pediatric Illness

Bhargavi Manchikalapati¹, Shammi Shaik², Savithri Bai Jhandavath³,
Dhachinamoorthy Duraiswamy⁴, Ram Chandra Reedy Linga⁵.

¹Assistant Professor, QIS College of Pharmacy, Ongole, Andhra Pradesh, India.

⁴Principal, QIS College of Pharmacy, Ongole, Andhra Pradesh, India

⁵Professor and HOD, QIS College of Pharmacy, Ongole, Andhra Pradesh, India

^{2,3} Pharm -D Department of Pharmacy Practice QIS College of Pharmacy, Ongole, Andhra Pradesh, India

Abstract

Reye syndrome is a rare but dangerous illness that frequently results in death. About 30–40% of cases result in death due to brainstem damage. The illness is frequently preceded by a viral infection, with a 3-5 day intermediate disease-free interval. The biological cause of Reye-like symptoms is a broad defect in mitochondrial metabolism that ultimately results in metabolic failure in the liver and other tissues. The cause of "classical" Reye syndrome is not known. Theoretically, the syndrome could result from an aberrant response to the prior viral infection. This response is determined by host genetic factors but can also be impacted by a range of external stressors. Consequently, a wide range of infections and diseases may manifest clinically as Reye-like symptoms. A wide range of toxic drugs, such as aspirin, and chemicals are examples of exogenous agents. Children with Reye syndrome frequently experience vomiting and confusion, which quickly progresses to a coma and death. This is a syndrome that often appears in the days after an aspirin-treated viral illness has healed. Reye syndrome may also occur as a result of or be predisposed to by inborn metabolic abnormalities, particularly those pertaining to fatty acid metabolism, medication reactions, and environmental contaminants. Both laboratory tests and clinical signs support this diagnosis. Misdiagnosis can occur due to inborn metabolic diseases that resemble Reye's syndrome, especially in children under three years old. Reye's syndrome-like symptoms are more likely to be caused by inborn metabolic problems as the incidence of Reye's syndrome declines.

Key words

Influenza, Aspirin, Varicella, Hypoglycemia, Encephalopathy, Chicken fox.

1. Introduction

Reye syndrome has been associated to a number of viral infections, most notably the flu and varicella in young children. 1963 saw the discovery of Reye's syndrome by Australian pathologist R.D. Reye. Children and teenagers are affected by this rare and occasionally fatal illness.^[5] first Reye. A widespread observation of these disorders led to a severe ban on aspirin use in youngsters in the United States early in the 1970s. In the remaining patients, there is usually no screaming throughout recuperation; in 25 to 50 percent of instances, there is a death rate. The hallmark symptom of therapy testing occurs several

days after a common respiratory ailment. This shift in mental state occurs. Reye syndrome, however, lacks a test. [56,57]

It usually begins in children as vomiting and confusion that soon progresses to a coma and death. These diseases are typified by recurring episodes, the disorder running in siblings, hypoglycemia on a regular basis, enlarged hearts, and muscle weakness.

This syndrome often appears in the days following the resolution of a viral illness for which aspirin was administered. Inborn metabolic anomalies, particularly those pertaining to the metabolism of fatty acids, medication interactions, and toxins, may either be the cause of Reye syndrome or predispose to it. Reye's syndrome usually begins with an upper respiratory, gastrointestinal, or flu-like viral illness. Infection with influenza varicella is often linked to Reye's syndrome in the United States. A few days later, there is an abrupt clinical decline followed by severe vomiting. In addition to encephalopathy, delirium, stupor, and lethargy may occur.

Aspirin should be administered with caution to children and teenagers suffering from fever or pain because it has been linked to Reye syndrome. Aspirin is safe for children over three, but it should never be given to adolescents or teenagers with symptoms similar to the flu or chicken pox. If your child is experiencing fever or pain, you might consider giving them acetaminophen (found in Tylenol) or ibuprofen (found in Advil and Motrin, among other brands).. [38,34,39]

2. Epidemiology

Since 1994, less than two cases of Reye's syndrome have been reported annually, making it an extremely unusual diagnosis. But since it's no longer required to report cases to the CDC, the actual incidence might not be known. Although occurrences have been documented in infants younger than a year old, the peak period is between the ages of 5 and 14. Reyes syndrome instances were documented by national surveillance in 1973^[6,9]. The CDC documented 556 instances between 1979 and 1980. The CDC documented 1,207 cases of Reye's syndrome in the US between December 1980 and November 1997. From an average of 100 cases annually in 1985–1986 to an average of 36 cases annually in 1987–1993 was the decline in incidence.

From 1991 to 1994, the frequency fell precipitously in the United States, from 0.2 to 1.1 cases per million people^[1,2]. There were 454 Reye's syndrome cases documented in the US in 1977. Out of 373 instances that were pursued, 42% of patients passed away and 11% survived with ongoing brain injury. Viral epidemics, particularly those caused by varicella and influenza B, enhanced the incidence. The number of instances of Reye's syndrome in the US has drastically fallen from 555 in 1980. Less than two instances were reported annually in the US between 1994 and 1997^[7,11]. Reye syndrome has an approximate 40% case-fatality rate, with a higher incidence in men than in women. In the UK, 597 instances were reported between 1981 and 1996. Reye's syndrome incidence dramatically decreased following 1986 aspirin-related warnings, peaking in 1986 at 0.63 cases per 100,000 children under the age of twelve. From 0.11 cases per 100,000 in 1990–1991 to 1983–1984. 155 of the 597 cases—76 including IEM—were eventually reclassified.^[5,3,32]

2.1 Age and social class: In the US, middle-class white children over three years old account for the majority of RS cases, although a sizable fraction of infant cases are from the lower-class black community. In the first year of the UK RS surveillance program, white people made up the majority of cases reported, and the majority of cases were under 3 years old. When it comes to newborns, RS can be distinguished from other encephalopathy-causing conditions such as heat stroke and toxic or metabolic illnesses.^[4,55]

2.2 Genetic predisposition: Reports of recurring episodes in the same individual and familial clustering of RS (but not in identical twins) do not distinguish between hereditary and environmental variables. Finding metabolic conditions that mimic RS is crucial in these situations.⁵. Siblings with comparable prodromal illnesses who later develop RS after recovering point to unusual processes.^[3,47]

3. Etiology

Reye syndrome's (RS) cause is yet unknown. Because of its frequent correlation with a previous viral infection, such as varicella or influenza B, it is categorized as a two-phase sickness. Though not transmissible, RS can strike a child more than once because of a lack of natural immunity.

The viruses that cause RS most frequently are the varicella-zoster virus and influenza viruses A and B. Several other diseases have also been linked to RS, including adenovirus, coxsackievirus, measles, cytomegalovirus, Epstein-Barr virus, HIV, retrovirus, hepatitis virus types A and B, mycoplasma, chlamydia, pertussis, shigella, salmonella, and polio.

The chance of having RS is higher in children who use aspirin for an extended period of time. In addition, a number of additional substances have been proposed as possible Reye's Syndrome causes, including aflatoxin, pesticides and insecticides, antiemetics, margosa oil, and bacterial endotoxins.^[43,52]

There is debate concerning the cause of RS. Certain specialists believe that the high incidence rate in the early stages of the disease, together with the sharp fall in the 1980s, were caused by early cases of inherited metabolic disorders being misdiagnosed. Common metabolic illnesses such as methylmalonic acidemia, hereditary fructose intolerance, 3-hydroxy-3-methyl-glutarate lyase deficiency, and single enzyme deficiencies of primary carnitine insufficiency could be clinically mistaken with real RS. Although frozen liver tissue samples are now able to be used to diagnosis certain hereditary metabolic diseases, many previous autopsies were unable to obtain these samples.^[46,20]

4. Stages

Reye syndrome is divided into six stages by the National Reye Syndrome Surveillance System:

Stage 1: sluggishness, sleepiness, and trouble waking up.

Stage 2: deluded, aggressive, and disoriented, with motions that are semi-purposeful and intentional.

Stage 3: coma, stiff pupils with preserved light and reflexes in the eyes

Stage 4: loss of pupillary reflexes, stiffness, and severe coma.

Stage 5: pupillary light sensitivity, areflexia, nerveless, flaccid paralysis

Stage 6: Not classifiable since being treated with Kuraray or other medications^[10,9,12]

5. Symptoms

Reye's syndrome typically progresses in two phases. Reye syndrome patients frequently have siblings or playmates who have recently experienced infectious disorders such as chicken pox, measles, herpes simplex, or infectious hepatitis.^[54,16,26]

The illness Reye's syndrome is biphasic. A viral prodrome that lasts several days and a remission that lasts one to five days define the first phase. Acute emergence of several symptoms that result in a medical presentation is the second stage. There is a consistent pattern to these symptoms: a decrease in the Glasgow Coma Scale score, which is typically observed in up to 40% of cases, is followed by easy and frequent vomiting, which is followed by quickly progressing neurological deterioration with irritability and potential seizures.^[14,28]

6. Pathophysiology

Reye's syndrome appears to be linked to mitochondrial damage in the context of viral illness, while the precise pathophysiology of the condition is unknown. Damage to the mitochondria of cells caused by aspirin can occur or persist, interfering with the metabolism of fatty acids. Elevated ammonia levels brought on by mitochondrial malfunction in the liver are most likely the source of the neurological symptoms of Reye's syndrome. As a result of astrocyte swelling brought on by hyperammonemia, widespread cerebral edema and a rise in intracranial pressure can occur. Pathological investigations have revealed astrocyte enlargement, neuronal loss, renal fatty degeneration, and mitochondrial enlargement and decrease.^[22,23,45]

Background

Reye syndrome, which typically follows chicken pox or influenza, is marked by encephalopathy and fatty liver degeneration. Due to the possibility of Reye's syndrome, children with these viral infections have not been prescribed salicylates since 1980.^[22,53]

7. Diagnosis

The results of laboratory tests indicate liver dysfunction characterized by prolonged prothrombin time, hyperammonemia, and increased serum aminotransferases. Serum bilirubin levels are typical. About 40% of individuals have hypoglycemia, which is particularly common in younger patients. Usually present is respiratory alkalosis, which frequently coexists with concurrent metabolic acidosis. There is a rise in serum creatine phosphokinase. Elevated blood concentrations of amino acids, hyperuricemia, lactic acid, and free fatty acid are among the other laboratory abnormalities associated with Reye's syndrome. The cerebral fluid examination is unremarkable, with the exception of elevated blood pressure and sporadic hypoglycemia.^[18,50]

On rare occasions, bleeding was seen. Lethargy, stupor, delirium, and irritability are frequent symptoms. The patient may adopt a decorative position with bent elbows, clasped hands, and extended legs when he is fully unconscious.^[13,49,25]

8. Treatment

Reye's syndrome has mostly been treated with supportive care, which includes replacing lost bodily fluids, treating metabolic acidosis and hypoglycemia, and, if needed, giving oxygen and blood transfusions. The use of steroids was not linked to any observable benefit. To lessen brain swelling, very few kids were given mannitol or hypertonic glucose. liver failure exchange transplant. One patient group with increased SCOT and blood ammonia showed chemical signs of improvement; a 16-month-old kid receiving peritoneal dialysis repaired the metabolic acidosis by eliminating hydrogen ions and insoluble ammonium. While one patient's response to this medication was positive, more research has to be done. It is advised to sterilize or alter the gut flora, though its benefits are yet unknown.^[15,24]

9. Supportive therapy

The maximum volume of liquid allowed is 1200 ml/M2, and monitoring is done for specific gravity, blood pressure, urine output, and central venous pressure. Brain edema is managed with mannitol (30 g/M2 injected over 30 minutes). It has recently been suggested that the effectiveness of supportive care can be increased by directly measuring intracranial pressure through the hand-skull subdural gap using a catheter. Brain edema has been suggested to be treated with corticosteroids, particularly dexamethasone. It is uncertain how corticosteroids affect cerebral edema in humans and laboratory animals, and they had no beneficial effect on our patients.^[29,33]

The maximum volume of liquid allowed is 1200 ml/M2, and monitoring is done for specific gravity, blood pressure, urine output, and central venous pressure. Brain edema is managed with mannitol (30 g/M2 injected over 30 minutes). It has recently been suggested that the effectiveness of supportive care can be increased by directly measuring intracranial pressure through the hand-skull subdural gap using a catheter. Brain edema has been suggested to be treated with corticosteroids, particularly dexamethasone. It is uncertain how corticosteroids affect cerebral edema in humans and laboratory animals, and they had no beneficial effect on our patients.

The increase in free fatty acids observed in the disease led to a suggestion that this treatment may reduce lipolysis and serum free fatty acids, resulting in improvement of encephalopathy. As discussed, the association of serum free fatty acids with encephalopathy is currently unclear. Although glucose is naturally needed for energy, to replace liver glycogen, and to correct and prevent hypoglycemia, insulin-hypertonic glucose therapy should be discontinued.^[48,51]

- Children with severe Reye syndrome require:
 - Endotracheal intubation.
 - A mechanical respirator that controls hyperventilation and maintains an arterial carbon dioxide pressure of 25–30 mm Hg.
 - Pancuronium bromide, 0.1–0.2 mg/kg to prevent muscle paralysis and thus facilitate adequate mechanical ventilation.
 - Central venous or SwanGanz catheter. If blood volume is depleted, it must be expanded with an appropriate colloid solution. Any electrolyte imbalance must be corrected. If a SwanGanz catheter is used, the pulmonary artery wedge pressure should be maintained at 3 to 5 mm Hg.
 - Intravenous fluids containing 15-20% glucose are distributed at a rate of approximately 1200 mL/inch of body surface area over 24 hours. Blood sugar levels should be maintained between 8.3-10.0 mmol/l (150-180 mg/dl).^[19,21,30]
 - Ventricular, subdural subarachnoid monitoring device or continuous pressure recording. If the patient has a prolonged intracranial prothrombin time, fresh frozen plasma or partial transfusion can be used to

minimize bleeding.

- Arterial line for both arterial pressure and arterial oxygen monitoring. Adequate cerebral perfusion must be achieved (mean arterial pressure minus intracranial pressure) of at least 50 mm Hg, mean arterial pressure greater than 90 mm Hg, and arterial oxygen pressure between 100 and 150 mm Hg.
- If necessary, a cooling blanket that keeps the body temperature at 37°C.
- If the intracranial pressure is more than 20 mmHg, mannitol, 0.25 g/kg as a 20% solution, administered intravenously over 10-20 minutes. In acute cases, the most effective way to quickly lower intracranial pressure while waiting for the effect of mannitol is manual hyperventilation.^[36,31,44]
- Check serum osmolality every 4 hours to maintain this less than 320 mOsm/kg.
If intracranial pressure cannot be reduced with mannitol, or if serum osmolality is higher more than 320 mOsm/kg, causes coma either with phenobarbital¹⁰ or pentobarbital.⁸ with phenobarbital, give slowly at 50 mg/kg IV drip at first, while carefully controlling blood pressure; for for the next 3 days give 25 mg/kg in three in divided doses. It should be preserved blood level around 5-7 mg/dL. With pentobarbital give 3 initially 5 mg/kg intravenously, then give 1 to 2 mg/kg .h. Titiri dose to maintain blood levels 2.5 to 4.0 mg/dL. If barbiturate coma fails reduce intracranial pressure, cool the body to 31-33 degrees. If there is intracranial pressure still high, consider bifrontal decompressive craniectomy.^[37,42,41]

10. Conclusion

Reye's syndrome is a severe, acute metabolic encephalopathy that usually affects newborns and children. The disorder's pathophysiology is uncertain, though a number of environmental contaminants have been implicated. The treatment is mostly supportive. However, with more intensive medication regimens developed during the last ten years, the prognosis has significantly improved. In most series, early reports showed a death rate of 80% to 90%. Current mortality rates range from 10% to 40%. It is unclear if this is due to more vigorous treatment, earlier disease detection, or the identification of many milder instances.. Many more patients survive the acute sickness for unknown reasons. The outcome is favorable for the majority of those children. They may regain entirely normal function with no long-term neurologic impairments. Early diagnosis and proper supportive therapy appear to be critical in slowing the progression of the disease and ensuring a better result for these youngsters.

11. References

- 1.Chornomydz I, Boyarchuk O, Chornomydz A. REYE (RAY'S) SYNDROME: A PROBLEM EVERYONE SHOULD REMEMBER. Georgian Med News. 2017 Nov;(272):110-118. [PubMed] [Reference list]
2. Kramer MS. Kids versus trees: Reye's syndrome and spraying for spruce budworm in New Brunswick. J Clin Epidemiol. 2009 Jun;62(6):578-81. [PubMed] [Reference list]
3. Luscombe FA, Monto AS, Baublis JV. Mortality due to Reye's syndrome in Michigan: distribution and longitudinal trends. J Infect Dis. 1980;142:363-371
4. Pessoa FS, Lacerda EMD, Gonçalves VC, Tanaka BN. Case Report: MIS-C Temporarily Associated With COVID-19 Complicated by Reye's Syndrome. Front Pediatr. 2021. 9:650697. [QxMD MEDLINE Link]. [Full Text]
5. 15 New World Encyclopedia. Reye's Syndrome. Last updated September 5, 2008. Available at http://www.newworldencyclopedia.org/entry/Reye%27s_syndrome..
6. Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB. Reye's syndrome in the United States from 1981 through 1997. N Engl J Med. 1999. May 6;340(18):1377-1382. [PubMed] [Google]
7. Rennebohm RM., Heubi J.E., Daugherty C.C. and Daniels S.R. (1985) Reye's syndrome in children Receiving salicylate therapy for connective tissueDisease. J. Pediatr. 107,877

8. American Academy Of Pediatrics Committee On Infectious Diseases. (1982).
9. Aspirin And Reye's syndrome. *Pediatrics*, 69, 810-812. Atkins, J., & Haponik
10. Dvorackova, I., Vortel, V. and Hroch, M.: Encephalitis syndrome with fatty degeneration of Viscera. *Arch. Path.* 81: 240, 1966.
10. Curry, A. S., Guttman, H. A. and Price, D.
11. Pugliese A, Beltramo T, Torre D. Reye's and Reye's-like syndromes. *Cell Biochem Funct* 2008;
12. Glasgow JF, Middleton B. Reye syndrome—insights on causation and prognosis. *Archives of Disease in Childhood* 2001; 85:351-353
13. Becroft, D. M. O.: Syndrome of encephalopathy And fatty degeneration of viscera in New Zealand children. *Brit. Med. J.* 2: 135, 1966.
19. Scott, H
14. DeLong GR, Glick TH. Encephalopathy of Reye's Syndrome: a review of pathogenetic hypotheses. *Pediatrics* 1982; 69: 53-63.
15. Noor A, Gradidge E. A Case of Reye Syndrome Caused by Influenza A Virus. *Ochsner J.* 2018 Winter; 18(4):425-427. Doi: 10.31486/toj.18.0098. PMID: 30559633; PMCID: PMC6292460.
16. David, R. B.: Glucose-Insulin Therapy and Intracranial Pressure Monitoring in Reye's Syndrome, in Pollack, J. D. (ed.), *Reye's Syndrome* (New York: Grune & Stratton, Inc., 1975).
17. Kindt, G. W., Waldman, J., Kohl, S., Baublis, J., and Tucker, R. P.: Intracranial pressure in Reye's syndrome. Monitoring and control, *JAMA* 231:822, 1975.
18. Benson, V. M., McLaurin, R. L., and Foulkes, E. C.: Traumatic cerebral Edema. An experimental model with evaluation of dexamethasone, *Arch. Neurol.* 23:179, 1970.
19. DeVivo, D. C., Keating, J. P., and Haymond, M. W.: Intensive Supportive Approach to the Treatment of Reye's Syndrome, in Pollack, J. D. (ed.), *Reye's Syndrome* (New York: Grune & Stratton, Inc., 1975).
20. Goldschmidt, M. N., and Bailey, D. W.: Management of Reye's syndrome, *N. Engl. J. Med.* 287:255, 1972.
21. Brown, R. E., Madge, G. E., and Schiller, H. M.: Observations on the Pathogenesis of Reye's syndrome *South. Med. J.* 64:942, 1971.
22. Uppala R, Dudiak B, Beck ME, Bharathi SS, Zhang Y, Stolz DB, Goetzman ES. Aspirin increases mitochondrial fatty acid oxidation. *Biochem Biophys Res Commun.* 2017 Jan 08; 482(2):346-351.
23. Brain WR, Hunter D, Turnbull HM. Acute meningo-encephalomyelitis of childhood: report of 6 cases. *Lancet* 1929; 1:221-227..
24. Johnson GM, Scurletis TD, Carroll NB. A study of sixteen fatal cases of encephalitis-like disease in North Carolina children. *N C Med J* 1963; 24:464-473
25. Partin JS, Daugherty LANSKY LL: Clinical staging of Reye syndrome. *I Pediatr* 1976; 88: 1070- 1071
74. BRUNNER RL, O'GRADY Di, PARTIN IC, PARTIN JS, SCHUBERT WK: Neuro-psychologic consequences of Reye syndrome. *I Pediatr* 1979; 95: 706- 711
75. DAVIDSON PW, WILLOUGHBY RH. OTUAMA LA, SWISHER CN, BENJAMINS D: Neurological and intellectual sequelae of Reye's syndrome: a preliminary report. In POLLACK ID (ed): *Reye's Syndrome*, Grune, New York, 1974: 55-59
- ty CC, McAdams AJ, Partin JC, Schubert WK. A comparison of liver ultrastructure in salicylate intoxication and Reye's syndrome. *Hepatology* 1984; 4:687-690

26. Clauson KA, Santamarina ML, Buettner CM, Cauffield JS. Evaluation of presence of aspirin-related warnings with willow bark. *Ann Pharmacother*. 2005 Jul-Aug;39(7-8):1234-7.
27. Matsuishi T, Yamaguchi Y, Terasawa K, Ohtaki E, Kimura A, Yamashita F. The differential diagnosis of Reye syndrome: muscle biopsy evaluation. *Brain Dev*. 1987;9(6):610-4.
28. Mitchell RA, Arcinue EL, Partin JC, Partin JS, Ram ML, Chang CH, Smialek J, Sarnaik A. Quantitative evaluation of the extent of hepatic enzyme changes in Reye syndrome compared with normal liver or with non-Reye liver disorders: objective criteria for animal models. *Pediatr Res*. 1985 Jan;19(1):19-22.
29. Corey L, Rubin RJ: Reye's syndrome 1974: An epidemiological assessment, In Pollack JD (Ed): *Reye's Syndrome*. New York, Grune & Stratton, 1975, pp 179-18.
30. Trauner DA: Treatment of Reye's syndrome. *Ann Neurol* 1980; 7:2-5 35.
31. Marshall LF, Shapiro HM, Rauscher A, et al: Pentobarbital therapy for intracranial hypertension in metabolic coma-Reye's syndrome. *Crit Care Med* 1978 Jan-Feb; 6:1-5 32
- 32.. Brown RE, Burckart G, Thompson R: Barbiturate-associated mor- bidity and mortality in Reye's syndrome. *J Natl Reye's Syndrome Foun- dation* 1982; 3(1):29 37
- 33.. Brunner RL, O'Grady DJ, Partin JC, et al: Neuropsychologic consequences of Reye's syndrome. *J Pediatr* 1979; 95:706-711.
34. . Partin JS, McAdams AJ, Partin JC, et al. Brain ultrastructure in Reye's syndrome. 11. *Neuropathol Exp Neurol* 1978 37:796-819.
- 35.. Robinson BH, Taylor J, Cutz E, et al. Reye's syndrome: preservation of mitochondrial enzymes in brain and muscle compared with liver. *Pediatr Res* 1978; 12:1045-1047.
- 36.. Heubi JE, Daugherty CC, Partin JS, et al. Grade I Reye's syndrome-Outcome and predictors of progression to deeper coma grades. *N Engl J Med*. Partin JS, Daugherty CC, McAdams AJ, et al. A comparison of liver ultrastructure in salicylate intoxication and Reye's syndrome. *Hepatology* 1984; 4:687-690. LANSKY LL: Clinical staging of Reye syndrome. *I Pedjair* 1976
37. You KS. Salicylate and mitochondrial injury in Reye's syndrome. *Science* 1983; 221:163-165.
38. Segalman TY, Lee CP. Reye's syndrome: plasma-induced alterations in mitochondrial structure and function. *Arch Biochem Biophys* 1982; 214:522-530 1984; 311:1539-1542.
39. Kritchevsky, D., L. M. Davidson, H. K. Kim, and S. Malhotra. 1973. Quantitation of serum lipids by a simple TLC-charring method. *Clin. Chim. Acta*. 46:63-68.
40. Tanaka, K., D. G. Hine, A. West-Dull, and T. B. Lynn. 1980. Gas-chromatography method for analysis of urinary organic acids. *Clin. Chem*. 26:1839-1853.
41. Glick, T. H., Ditchek, N. T., Salitsky, S. and Freimuth, G. J.: Acute encephalopathy and hepatic dysfunction—associated with chickenpox in siblings. *Amer. J. Dis. Child*. 119: 68, 1970.
42. Bradford, W. D. and Latham, W. D.: Acute encephalopathy and fatty hepatomegaly. *Amer. J. Dis. Child*. 114: 152, 1967.

43. Halpin TJ, Holtzhauer FJ, Campbell RJ, et al. Reye's syndrome and medication use. *JAMA* 1982; 248: 687-91.
44. Starko KM, Mullick FG. Hepatic and cerebral pathology findings in children with fatal salicylate intoxication: further evidence for a causal relation between salicylate and Reye's syndrome. *Lancet* 1983; i: 326-9.
45. Brown AK, Fikrig S, Finberg L. Aspirin and Reye syndrome. *JPediatr* 1983; 102:157-8.
46. Tamaoki Y, Kimura M, Hasegawa Y, et al. A survey of Japanese patients with mitochondrial fatty acid beta-oxidation and related disorders as detected from 1985–2000. *Brain Dev* 2002; 24: 675–80
47. Rahbeeni Z, Vaz F-M, Al-Hussein K, et al. Identification of two novel mutations in OCNT2 from two Saudi patients with systemic carnitine deficiency. *J Inherit Metab Dis* 2002; 25: 363–9.
48. Tasker RC. Update on pediatric neurocritical care. *Paediatr Anaesth*. 2014 Jul;24(7):717-23.
49. Ahrens-Nicklas RC, Edmondson AC, Ficicioglu C. An 8-year-old girl with abdominal pain and mental status changes. *Pediatr Emerg Care*. 2015 Jun;31(6):459-62.
50. Johnson GM, Sculetis TD, Carroll NB. A study of sixteen fatal cases of encephalitis – like disease in north Carolina children. *N C Med J* 1963;24:464-473.
51. Partin JS, Daugherty CC, McAdams, AJ, Partin JC, Schubert WK. A comparison of liver ultrastructure in salicylate intoxication and Reye's syndrome. *Hepatology* 1984;4:687-690.
52. Mitchell RA, Arcine EL, Partin JC, Partin JS, Ram ML, Chang CH, Smialek J, Sarnaik A. Quantitative evaluation of the extent of hepatic enzyme changes in Reye syndrome compared with normal liver or with non-REYE Liver Disorders; objective criteria for animal models. *Pediatr Res*. 1985 Jan;19(1):19-22.
53. Pugliese, A; Beltramo, T; Torre, D (October 2008). "Reye's and Reye's-like syndromes". *Cell Biochemistry and Function*. **26** (7): 741–6. doi:10.1002/cbf.1465. PMID 18711704. S2CID 22361194.
54. "NINDS Reye's Syndrome Information Page". *NINDS*. September 25, 2009. Archived from the original on August 1, 2016. Retrieved August 8, 2016.
55. Schrör, K (2007). "Aspirin and Reye syndrome: a review of the evidence". *Paediatric Drugs*. **9** (3): 195–204. doi:10.2165/00148581-200709030-00008. PMID 17523700. S2CID 58727745.
56. Mund ME, Gyo C, Brüggmann D, Quarcoo D, Groneberg DA. Acetylsalicylic acid as a potential pediatric health hazard: legislative aspects concerning accidental intoxications in the European Union. *J Occup Med Toxicol*. 2016;11:32. [[PMC free article](#)] [[PubMed](#)]
57. Brannelly NT, Hamilton-Shield JP, Killard AJ. The Measurement of Ammonia in Human Breath and its Potential in Clinical Diagnostics. *Crit Rev Anal Chem*. 2016 Nov;46(6):490-501. [[PubMed](#)] [[Reference list](#)]